Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr. Opin. Pediatr. 21, 365–372 (2009).
  MedlineGoogle Scholar
• 2. Jeon DG, Song WS. How can survival be improved in localized osteosarcoma? Expert Rev. Anticancer Ther. 10, 1313–1325 (2010). • A review of the most effective therapies that have been used for the treatment of osteosarcoma.
  MedlineGoogle Scholar
• 3. Luetke A, Meyers PA, Lewis I et al. Osteosarcoma treatment – where do we stand? Cancer Treat. Rev. 40, 523–532 (2014).
  MedlineGoogle Scholar
• 4. Harrison DJ, Geller DS, Gill JD et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev. Anticancer Ther. 18(1), 39–50 (2018).
  Medline CASGoogle Scholar
• 5. Hegde PS, Karanikas V, Evers S. The where the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865–1874 (2016).
  Medline CASGoogle Scholar
• 6. Miwa S, Shirai T, Yamamoto N et al. Current and emerging targets in immunotherapy for osteosarcoma. J. Oncol. 2019, 7035045 (2019).
  MedlineGoogle Scholar
• 7. Lussier DM, Johnson JL, Hingorani P et al. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J. Immunother. Cancer 3, 21 (2015). •• Suggests that the combination therapy with immune check-point inhibitors anti-PD-1 and anti-CTLA-4 may serve as a new candidate against tumor growth of metastatic osteosarcoma.
  MedlineGoogle Scholar
• 8. Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69, 2514–2522 (2009). •• Reports that the novel role of tyrosine kinase inhibitor can remodel the tumor microenvironment and could serve as a likely therapeutic intervention in cancer therapies.
  Medline CASGoogle Scholar
• 9. Castillo-Avila W, Piulats JM, Garcia Del Muro X et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin. Cancer Res. 15, 3384–3395 (2009).
  Medline CASGoogle Scholar
• 10. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Am. Soc. Clin. Oncol. 26, 15 (2008).
  Google Scholar
• 11. Jaini R, Rayman P, Cohen PA et al. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int. J. Cancer 134, 1695–1705 (2014). • Presents the evidences for the key role of sunitinib in cancer progression.
  Medline CASGoogle Scholar
• 12. Farsaci B, Higgins JP, Hodge JW et al. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int. J. Cancer 130, 1948–1959 (2012).
  Medline CASGoogle Scholar
• 13. Seki N, Kan-O K, Matsumoto K et al. Interleukin-22 attenuates double-stranded RNA induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism. Biochem. Biophys. Res. Commun. 494, 242e248 (2017). • Establishes the molecular basis of PD-L1 blockade-dependent immunotherapy and provides a rationale for immune checkpoint blockade as a promising approach in cancer treatment.
  Google Scholar
• 14. Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15, 971–979 (2009).
  Medline CASGoogle Scholar
• 15. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
  Medline CASGoogle Scholar
• 16. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  Medline CASGoogle Scholar
• 17. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
  Medline CASGoogle Scholar
• 18. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015). • A review of immune checkpoint blockade may be the most effective therapy for the treatment of cancer.
  Medline CASGoogle Scholar
• 19. Cao M, Liu C. Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91 (4), 598–608 (2011).
  Medline CASGoogle Scholar
• 20. Hu X, Cao J, Hu W et al. Multicenter Phase II study of apatinib in nontriplenegative metastatic breast cancer. BMC Cancer 2014(14), 820 (2009).
  Google Scholar
• 21. Yu H, Kortylewski M, Pardoll D et al. Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment. Nat. Rev. Immunol. 7, 41–51 (2007). •• Presents the important role of STAT3 in the tumor microenvironment.
  Medline CASGoogle Scholar
• 22. Yu H, Pardoll D, Jove R et al. STATS in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798–809 (2009).
  Medline CASGoogle Scholar
• 23. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 3, 5665–5669 (2007).
  Google Scholar
• 24. Potapova O, Laird AD, Nannini MA et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther. 5, 1280–1289 (2006).
  Medline CASGoogle Scholar
• 25. Draghiciu O, Nijman HW, Hoogeboom BN et al. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology 4(3), e989764 (2015).
  MedlineGoogle Scholar
• 26. Trapani JA, Smyth MJ et al. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2 (10), 735–747 (2001).
  Google Scholar
• 27. Preston CC, Maurer MJ, Oberg AL et al. The ratios of CD8⁺T cells to CD4⁺ CD25⁺ Foxp3⁺ and Foxp3⁻ T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS ONE 8, e80063 (2013).
  MedlineGoogle Scholar
• 28. Lussier DM, Zamarin D, Munn DH et al. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J. Immunother. Cancer 3, 21 (2015). •• Suggests the crosstalk between poor clinical outcome of the cancer and immune cells and provides a novel therapeutic approach for the treatment of cancer.
  MedlineGoogle Scholar